AU2015356078B2 - Adjuvant composition - Google Patents

Adjuvant composition Download PDF

Info

Publication number
AU2015356078B2
AU2015356078B2 AU2015356078A AU2015356078A AU2015356078B2 AU 2015356078 B2 AU2015356078 B2 AU 2015356078B2 AU 2015356078 A AU2015356078 A AU 2015356078A AU 2015356078 A AU2015356078 A AU 2015356078A AU 2015356078 B2 AU2015356078 B2 AU 2015356078B2
Authority
AU
Australia
Prior art keywords
nucleic acid
rna
dna
cancer
stranded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015356078A
Other languages
English (en)
Other versions
AU2015356078A1 (en
Inventor
Misako Matsumoto
Tsukasa Seya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute Of Advanced Immunotherapy
Original Assignee
Inst Of Advanced Immunotherapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Advanced Immunotherapy filed Critical Inst Of Advanced Immunotherapy
Publication of AU2015356078A1 publication Critical patent/AU2015356078A1/en
Assigned to Advanced Innovation Development Co. Ltd. reassignment Advanced Innovation Development Co. Ltd. Request for Assignment Assignors: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
Application granted granted Critical
Publication of AU2015356078B2 publication Critical patent/AU2015356078B2/en
Assigned to INSTITUTE OF ADVANCED IMMUNOTHERAPY reassignment INSTITUTE OF ADVANCED IMMUNOTHERAPY Request for Assignment Assignors: Advanced Innovation Development Co. Ltd.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015356078A 2014-12-02 2015-12-01 Adjuvant composition Active AU2015356078B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014244421A JP6453063B2 (ja) 2014-12-02 2014-12-02 アジュバント組成物
JP2014-244421 2014-12-02
PCT/JP2015/083825 WO2016088784A1 (ja) 2014-12-02 2015-12-01 アジュバント組成物

Publications (2)

Publication Number Publication Date
AU2015356078A1 AU2015356078A1 (en) 2017-06-29
AU2015356078B2 true AU2015356078B2 (en) 2021-09-16

Family

ID=56091725

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015356078A Active AU2015356078B2 (en) 2014-12-02 2015-12-01 Adjuvant composition

Country Status (7)

Country Link
US (1) US10105385B1 (enExample)
EP (1) EP3228322B8 (enExample)
JP (1) JP6453063B2 (enExample)
CN (1) CN106999573B (enExample)
AU (1) AU2015356078B2 (enExample)
CA (1) CA2969024C (enExample)
WO (1) WO2016088784A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017221076A1 (en) * 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
US11065331B2 (en) 2016-07-27 2021-07-20 Advanced Innovation Development Co. Ltd. Immune adjuvant for cancer
JP7219212B2 (ja) * 2016-09-06 2023-02-07 エフ．ホフマン－ラ ロシュ アーゲー Ｍｈｃ結合ペプチドアレイおよびその使用方法
EP4632069A1 (en) 2022-12-05 2025-10-15 Aomori Yamada Gakuen Educational Corporation Nucleic acid adjuvant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008065752A1 (fr) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Agent immunothérapeutique contenant un arndi en tant que principe actif
WO2012014945A1 (ja) * 2010-07-28 2012-02-02 国立大学法人北海道大学 アジュバント活性を有する新規核酸およびその利用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138681A0 (en) * 1998-03-26 2001-10-31 American Cyanamid Co Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
EP2085479A1 (en) * 2008-01-31 2009-08-05 Institut Pasteur Reverse genetics of negative-strand rna viruses in yeast
CN102000330B (zh) * 2010-09-14 2012-08-29 中国人民解放军第二军医大学 一种核酸疫苗佐剂及其构建方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008065752A1 (fr) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Agent immunothérapeutique contenant un arndi en tant que principe actif
WO2012014945A1 (ja) * 2010-07-28 2012-02-02 国立大学法人北海道大学 アジュバント活性を有する新規核酸およびその利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZUNIGA ET AL, "Attenuated measles virus as a vaccine vector", VACCINE, ELSEVIER, AMSTERDAM, NL, (2007-03-29), vol. 25, no. 16, doi:10.1016/J.VACCINE.2007.01.064, ISSN 0264-410X, pages 2974 - 2983 *

Also Published As

Publication number Publication date
JP2016108250A (ja) 2016-06-20
EP3228322B8 (en) 2019-06-19
CA2969024A1 (en) 2016-06-09
EP3228322B1 (en) 2019-04-10
JP6453063B2 (ja) 2019-01-16
US10105385B1 (en) 2018-10-23
WO2016088784A1 (ja) 2016-06-09
EP3228322A4 (en) 2018-05-30
US20180280425A1 (en) 2018-10-04
CA2969024C (en) 2022-05-24
AU2015356078A1 (en) 2017-06-29
EP3228322A1 (en) 2017-10-11
CN106999573B (zh) 2021-10-19
CN106999573A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
KR102527941B1 (ko) 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
JP7556848B2 (ja) ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物
EP2599866B1 (en) Novel nucleic acid having adjuvant activity and use thereof
JP2021512090A (ja) 免疫細胞に薬剤を送達するための組成物及び方法
JP2010536787A (ja) Ｔｏｌｌ様受容体モジュレータ
JP2015529073A (ja) 生物可逆性基を有するポリヌクレオチド
KR20240043822A (ko) 올리고뉴클레오티드 제제를 위한 올리고뉴클레오티드 기반 전달체 및 이의 사용 방법
WO2019048632A1 (en) STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
CN114585633A (zh) 寡核苷酸缀合物组合物和使用方法
CA2969024C (en) Adjuvant composition
WO2022122872A1 (en) Therapeutics for the treatment of neurodegenerative disorders
CN117343965B (zh) 核酸载体、核酸药及其制备方法和应用
US20250002921A1 (en) SPHERICAL NUCLEIC ACIDS FOR cGAS-STING AND STAT3 PATHWAY MODULATION FOR THE IMMUNOTHERAPEUTIC TREATMENT OF CANCER
WO2019143831A1 (en) Compositions and methods for increasing expression of scn2a
JP2025528102A (ja) アデニル酸シクラーゼ９（ａｃ９）を阻害するための組成物及び方法
US20240200064A1 (en) Gene therapy for inflammatory conditions
JP2025536260A (ja) 細胞透過性抗体の組成物および使用方法
CN121046378A (zh) 一种抑制jak1基因表达的干扰rna及其应用

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ADVANCED INNOVATION DEVELOPMENT CO. LTD.

Free format text: FORMER APPLICANT(S): NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY

PC1 Assignment before grant (sect. 113)

Owner name: INSTITUTE OF ADVANCED IMMUNOTHERAPY

Free format text: FORMER APPLICANT(S): ADVANCED INNOVATION DEVELOPMENT CO. LTD.

FGA Letters patent sealed or granted (standard patent)